# Evonik account plan

> Evonik is an Essen-based specialty chemicals group with FY2025 sales of €14,069 million, 31,053 employees and production at 98 locations in 27 countries.

## At a glance

Evonik is a global specialty chemicals company headquartered in Essen, Germany, selling intermediates such as silicas, amino acids, polymers, additives and pharmaceutical ingredients mostly to industrial customers; no end-market accounts for more than 20% of sales. It produces at 98 locations in 27 countries and makes 82% of sales outside Germany. FY2025 sales were €14,069 million (-7%), adjusted EBITDA €1,874 million and net income €265 million, with 31,053 employees at year-end. RAG-Stiftung is the majority shareholder. Since early September 2026 Dr. Claus Rettig has led the company as interim CEO while CEO Christian Kullmann is ill.

## Business units

- **Advanced Technologies** (43% of FY2025 sales (€5,973 million)): Technology- and cost-leadership businesses: Inorganics (silicas, silanes, hydrogen peroxide), Organics (crosslinkers, polyamide 12, PEEK, SEPURAN membranes) and Animal Nutrition (methionine, lysine). Q3 2026 sales rose 19% to €1,713 million and adjusted EBITDA 87% to €377 million on amino acid prices. Led by Dr. Claudine Mollenkopf.
- **Custom Solutions** (39% of FY2025 sales (€5,492 million)): Innovation-driven, customer-specific products: Additives (PU foam, coating and oil additives, catalysts) and Care (pharmaceutical ingredients, lipids, medical materials, cosmetics). Q3 2026 sales rose 4% to €1,394 million, with nine-month adjusted EBITDA flat at €728 million. Led by Lauren Kjeldsen.
- **Infrastructure** (18% of FY2025 sales (€2,449 million)): Site services at Marl and Wesseling, carved out into SYNEQT GmbH from January 1, 2026, and the Oxeno C4 chemicals business, which is to be sold. Q3 2026 sales rose 13% to €648 million on Oxeno prices.

## Strategic priorities

- **ROCE of around 11%**: From 2026 ROCE is the central management metric, targeted at around 11% mid-term against 6.1% in 2025, with cash conversion above 40% and a solid investment grade rating.
- **Evonik Tailor Made cost programme**: Around €400 million of annual savings and 2,000 fewer jobs by end-2026, extended in June 2026 with around 3,200 more job cuts planned for 2027-2029.
- **Portfolio restructuring**: A new owner is sought for Oxeno, and SYNEQT is open to investors taking stakes or even a complete sale.
- **Innovation-led growth**: Next Generation Solutions reached 48% of sales with a target of over 50% by 2030, and three innovation growth areas should add €1.5 billion of sales by 2032.
- **Regional balance**: An aim of one-third of sales in each of Europe, the Americas and Asia, against EMEA 48%, Americas 29% and Asia-Pacific 23% in 2025.
- **Independence and selective consolidation**: Evonik rejected BASF's offer of €24 per share in November 2026 and says it wants to take part in consolidating the chemical industry from its own position.

## Latest results

In Q3 2026 sales rose 13% to €3,825 million and adjusted EBITDA 40% to €629 million (margin 16.4%), driven by Advanced Technologies after the war in the Middle East disrupted Asian competitors' supply. Over the nine months sales were €11,144 million (+4%), adjusted EBITDA €1,734 million (+14%) and free cash flow €601 million, while €313 million of structural expenses were booked for the second phase of Evonik Tailor Made. Guidance was raised at mid-year and then narrowed to the upper half of €2.0-2.2 billion adjusted EBITDA for 2026, with ROCE considerably above 2025 and capex around €750 million. Evonik expects the Middle East effects to keep fading and methionine prices to ease to year-end.

## Investments and deals

- **Capacity in growth businesses**: An alkoxides plant in Singapore, the first fumed aluminum oxide plant in Asia (Yokkaichi, Japan) for battery separators, SEPURAN membrane capacity in Austria and precipitated silica in Charleston (USA).
- **US backward integration and pharma lipids**: A methylmercaptan plant in Mobile (USA) completing methionine backward integration in 2026, and a pharmaceutical lipids plant in Lafayette (USA) with over US$100 million of US support.
- **Capex discipline**: Capex cash outflows were €748 million in 2025 and are guided around €750 million for 2026; every project must earn at least the cost of capital.
- **Innovation and venture**: R&D spend of €418 million in 2025, a new Evonik Innovation Factory, and Evonik Venture Capital with a €150 million Sustainability Tech Fund.

## Challenges and risks

- **Weak returns**: ROCE fell to 6.1% in 2025 against a 10.0% cost of capital, and 2025 guidance was cut twice after demand fell from Q2.
- **Chinese capacity and US tariffs**: New capacity and aggressive pricing from China and US trade policy weigh on prices; the CEO blamed an erratic U.S. tariff policy for the 2025 downswing.
- **Fading one-off demand**: 2026 gains came partly from customer stockpiling after the Middle East war and the Strait of Hormuz closure, effects that are fading.
- **Oxeno and impairments**: Oxeno took a €119 million impairment in H1 2026, and Q3 brought €264 million of impairments in Care and Organics.
- **Cyber and macro risks**: Cyberattacks, a fall in C4 chemical prices and volumes and a macroeconomic downturn are the material individual risks.

## What leadership says

> "The combination of an erratic U.S. tariff policy and the resulting uncertainty among our customers wrong-footed us." — Christian Kullmann, Chairman of the Executive Board, Statement at the Annual Shareholders' Meeting, June 3, 2026.

> "We intend to find a new owner for Oxeno, our C4 chemicals business." — Christian Kullmann, Chairman of the Executive Board, Statement at the Annual Shareholders' Meeting, June 3, 2026.

> "We hold our future in our own hands." — Christian Kullmann, Chairman of the Executive Board, Statement at the Annual Shareholders' Meeting, June 3, 2026.


## Where a supplier can help

- **Administrative efficiency**: Evonik Tailor Made (priority) targets leaner administration with flatter hierarchies, a fit for automation, shared-services and process software providers.
- **Carve-out and divestment support**: Selling Oxeno and opening SYNEQT to investors (priority: portfolio restructuring) need M&A advisory, separation IT and transitional services.
- **Plant engineering for growth capacity**: New plants in Singapore, Japan, Austria and the USA (investments) open opportunities for engineering, equipment and construction suppliers.
- **Cybersecurity**: Cyberattacks, with ransomware the main threat, are a material risk (challenge), pointing to OT and IT security services.
- **Commercial growth in the Americas and Asia**: The regional balance target (priority) favours partners in distribution, market intelligence and sales enablement outside Europe.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Evonik Financial and Sustainability Report 2025](https://www.evonik.com/content/dam/evonik/documents/Evonik_Financial_and_Sustainability_Report_2025.pdf)

Annual report · 2026-03-04

- Evonik is a global specialty chemicals group (Essen, Germany): FY2025 sales of €14,069 million (-7%), adjusted EBITDA €1,874 million (-9%), adjusted EBITDA margin 13.3%, 31,053 employees at year-end, production at 98 locations in 27 countries, 82% of sales outside Germany.
- Since April 1, 2025 the group runs on a new structure: two chemicals segments managed directly by executive board members, Advanced Technologies (43% of sales, cost and technology leadership) and Custom Solutions (39%, innovation-driven tailor-made solutions), plus Infrastructure (18%: Marl/Wesseling site services, now SYNEQT GmbH, and the Oxeno C4 business that is to be sold).
- 2025 was weaker than planned: demand fell sharply from Q2 and the guidance was cut twice; ROCE dropped to 6.1% against a 10% cost of capital and an ~11% mid-term target. Free cash flow was €695 million (cash conversion 37%), net financial debt €3,311 million, net income rose to €265 million.
- New financial framework: ROCE of around 11% mid-term, cash conversion above 40%, solid investment grade (S&P BBB+, Moody's Baa2 with positive outlook), and an earnings-linked dividend of 40-60% of adjusted net income from 2026; dividend cut to €1.00 for 2025.
- Cost programme Evonik Tailor Made: around €400 million of annual savings and 2,000 fewer jobs by end-2026, plus business-level optimisation programmes (Animal Nutrition, Health Care, high-performance polymers, silica, crosslinkers).
- Growth levers: Next Generation Solutions at 48% of sales (target over 50% by 2030); €1.5 billion of additional sales by 2032 from three innovation growth areas; aim of one-third of sales in each of Europe, the Americas and Asia (2025: EMEA 48%, Americas 29%, Asia-Pacific 23%).
- Capex held at €748 million of cash outflows; projects include alkoxides in Singapore, fumed aluminum oxide in Japan, methylmercaptan backward integration in Mobile (USA), pharmaceutical lipids in Lafayette (USA, over US$100 million of US support), SEPURAN membranes in Austria.
- Material risks: cyberattacks, a fall in C4 chemical prices and volumes, a macroeconomic downswing; Chinese capacity and pricing pressure and US tariff policy weigh on prices. 2026 guidance: adjusted EBITDA €1.7-2.0 billion, ROCE around the 2025 level, capex around €750 million.

### [Evonik Half Year Financial Report 2026 (Q2 / H1 2026)](https://www.evonik.com/content/dam/evonik/documents/Evonik%20Q2%202026_E.pdf)

Interim report · 2026-08-04

- H1 2026 (published August 4, 2026): sales €7,319 million (+1%, organic +4%, currency -3%), adjusted EBITDA €1,105 million (+3%), margin 15.1%, adjusted net income €454 million, net income €209 million, free cash flow €232 million.
- Q2 2026 was strong: sales €3,893 million (+11%), adjusted EBITDA €630 million (+24%), margin 16.2%, driven by customer stockpiling after the outbreak of the war in the Middle East in early March and supply bottlenecks at Asian competitors (Strait of Hormuz closure).
- Advanced Technologies benefited most: Q2 sales +9% to €1,647 million, adjusted EBITDA +25% to €333 million (margin 20.2%), with higher methionine/amino acid prices, crosslinkers and high-performance polymers.
- Custom Solutions Q2 sales +4% to €1,422 million and adjusted EBITDA +7% to €271 million; Infrastructure Q2 sales +28% to €749 million on Oxeno, with an Oxeno impairment of €119 million.
- Evonik Tailor Made was extended in June 2026: 2,800 jobs shed 2024-2026 and around 3,200 more planned for 2027-2029; the programme now runs until 2029.
- Guidance raised: adjusted EBITDA €2.0-2.2 billion (from €1.7-2.0 billion), ROCE slightly above 2025; capex around €750 million and cash conversion around 40% kept.
- Net financial debt rose to €3,620 million after the €466 million dividend; employees 30,356 at June 30, 2026 (-697 since year-end).

### [Evonik Quarterly Statement Q3 2026](https://www.evonik.com/content/dam/evonik/documents/Evonik%20Q3%202026%20E.pdf)

Interim report · 2026-11-03

- Q3 2026 (November 3, 2026): sales €3,825 million (+13%, organic +12% on significantly higher prices and slightly higher volumes), adjusted EBITDA €629 million (+40%), margin 16.4% (13.2%).
- Nine months: sales €11,144 million (+4%), adjusted EBITDA €1,734 million (+14%), margin 15.6%, adjusted net income €784 million, net income €156 million, free cash flow €601 million.
- Advanced Technologies drove the quarter: sales +19% to €1,713 million, adjusted EBITDA +87% to €377 million (margin 22.0%) on Animal Nutrition, crosslinkers and high-performance polymers.
- Custom Solutions Q3 sales +4% to €1,394 million, adjusted EBITDA +7% to €231 million; Infrastructure sales +13% to €648 million, adjusted EBITDA +48% to €80 million (Oxeno and SYNEQT).
- €313 million of structural expenses were booked in Q3 for the second phase of Evonik Tailor Made (around 3,200 job cuts 2027-2029); impairments of €264 million (Care, Organics) partly offset by €187 million of reversals in Animal Nutrition.
- Net financial debt fell to €3,292 million.
- Guidance narrowed to the upper half of €2.0-2.2 billion adjusted EBITDA; ROCE now considerably above 2025; the Middle East special effects are fading and methionine prices are expected to keep easing to year-end.

### [Statement by Christian Kullmann at the Annual Shareholders' Meeting, June 3, 2026](https://www.evonik.com/content/dam/evonik/documents/Statement%20Kullmann_HV_2026.pdf.coredownload.pdf)

Executive talk · Christian Kullmann, Chairman of the Executive Board (CEO) · 2026-06-01

- CEO Christian Kullmann's statement to the Annual Shareholders' Meeting on June 3, 2026, published in advance on June 1, 2026.
- On 2025: a strong start, then the "erratic U.S. tariff policy" hit customers; guidance could not be held from end-September; Evonik managed for liquidity and still delivered adjusted EBITDA of almost €1.9 billion and free cash flow of almost €700 million.
- Central objective: a ROCE of 11%. Levers: growth through innovation and portfolio restructuring (new owner sought for Oxeno; SYNEQT open to investors or "even a complete sale"), plus cost discipline.
- Next Generation Solutions reached 48% of group sales; new Evonik Innovation Factory to turn breakthroughs into industrial applications faster; growth investments in PA12 (drones, data centers), aluminum oxide for batteries in Japan, alkoxides for biodiesel in Singapore.
- Costs: Evonik Tailor Made plus business programmes; more than 850 fewer heads in 2025 and a further 1,000 in 2026.
- Dividend cut from €1.17 to €1 for 2025, then 40-60% of adjusted net income from 2026, backed by majority shareholder RAG-Stiftung; capital priorities: operating investment, then dividend, then debt reduction.
- New board pay: short-term bonus on adjusted EBITDA and free cash flow (50/50) with a ROCE hurdle; long-term on relative shareholder return (40%), ROCE (40%) and ESG (20%).
- Q1 2026 adjusted EBITDA was €475 million; customers were stocking up and methionine was in short supply; he confirmed €1.7-2.0 billion guidance while warning the second half "could therefore be weaker than the first half".

### [Evonik's interim CEO rejects BASF's offer (dpa report of FAZ interview)](https://www.cio.de/article/4245579/evonik-schmettert-basf-ab-kraft-fuer-eigene-uebernahmen.html)

Executive talk · Claus Rettig, Interim Chief Executive Officer · 2026-11-06

- dpa report (November 2026) of an interview interim CEO Claus Rettig gave the Frankfurter Allgemeine Zeitung, the week after Evonik said it was not negotiating a takeover with BASF.
- BASF had most recently offered €24 per Evonik share, valuing Evonik at more than €11 billion; Rettig reaffirmed that Evonik rejects the offer and stays independent; there is no counter-offer.
- His case: size alone is not better and other industries are moving towards focus; Evonik's own plan would deliver more than BASF offered (quotes translated from German).
- Evonik wants to take an active part in consolidating the chemical industry, has "financial firepower" (translated) and ideas, and opportunities in Germany, Europe and the USA, but is not pursuing acquisitions proactively so far.
- He dismissed talk that other bidders would come if BASF lost interest.
- Context in the same report: Rettig, 66, head of the Asia business, took over the duties of the ill CEO Christian Kullmann in early September; CFO Michael Rauch said on LinkedIn at the Q3 release that "Evonik is big enough" and its portfolio will be "much more attractive" after current measures (translation).

## Questions about Evonik

### What does Evonik do?

Evonik makes specialty chemicals such as silicas, amino acids for animal feed, high-performance polymers, additives and pharmaceutical ingredients, sold mostly to industrial customers worldwide.

### What is Evonik's revenue?

FY2025 sales were €14,069 million with adjusted EBITDA of €1,874 million. Nine-month 2026 sales were €11,144 million.

### How many employees does Evonik have?

31,053 at the end of 2025 and 30,356 at June 30, 2026, falling under the Evonik Tailor Made programme.

### Who leads Evonik?

Christian Kullmann is Chairman of the Executive Board; Dr. Claus Rettig has been interim CEO since early September 2026 while Kullmann is ill. Michael Rauch is CFO since May 1, 2026.

### Did Evonik accept BASF's takeover offer?

No. BASF most recently offered €24 per share, valuing Evonik at more than €11 billion; Evonik rejected it and says it remains independent.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
